Drafting from the manuscript: AG. scientific outcome after intravenous immunoglobulin (IVIG) treatment; a single with mild SARS-CoV-2 infections had favorable progression with no treatment spontaneously. The fourth affected individual had important SARS-CoV-2 infections and presented severe electric motor and sensory axonal neuropathy (AMSAN) with scientific features extremely suggestive of brainstem participation, aswell as positive anti-ganglioside antibodies (anti-GD1b IgG) and acquired incomplete improvement after IVIG. Conclusions We survey four situations of SARS-CoV-2-linked GBS. The period of 3?weeks between SARS-CoV-2 symptoms and neurological starting point, the clinical improvement after IVIG administration, and the current presence of positive anti-ganglioside antibodies in a single patient support the hypothesis of the immune-mediated post-infectious practice further. Systematic comprehensive antibody testing will help for an improved knowledge of physiopathology. Supplementary Details The web version includes supplementary Chloroxylenol material offered by 10.1007/s13760-021-01787-y. were not tested systematically. Nevertheless, there is no suggestive scientific context All sufferers offered sensorimotor symptoms and tendon areflexia about 3?weeks (20C24?times) after documented COVID-19 infections. SARS-CoV-2 infections was connected with a serious pulmonary disease in three of these. No various other GBS triggering event was discovered in all sufferers. CSF examinations uncovered albuminocytologic dissociation in two sufferers (case1 and case2) and an elevated albumin quotient in a single (case4). Positive serum anti-GD1b antibodies had been within one individual (case4). The last mentioned was the just patient Chloroxylenol displaying brainstem participation, with EDX (S4) appropriate for an severe electric motor and sensory axonal neuropathy (AMSAN), in support of partial scientific improvement after IVIG administration (2?g/kg for 5?times). This case once was reported [5] but EDX had not been available at that point. In the three various other situations, the EDX (S1-S3) was in keeping with severe inflammatory demyelinating polyneuropathy (AIDP) no serum anti-ganglioside antibodies had been discovered. Two of the various other sufferers (case1 and case2) provided serious SARS-CoV-2 infections and had great scientific final result after IVIG treatment (2?g/kg for 5?times). The 3rd other affected individual (case3) Chloroxylenol had minor SARS-CoV-2 infections and acquired spontaneously favorable progression without treatment. Debate We explain four situations of SARS-CoV-2-linked GBS, adding proof to the possible association between both of these entities. The lag time taken between COVID-19 infection as well as the neurological onset, the response to IVIG, and specially the existence of anti-ganglioside antibodies in a single patient are extremely suggestive of the post-infectious immune-mediated system. Our affected individual with positive anti-ganglioside antibodies (anti-GD1b IgG) was the only person with brainstem MEN2B participation, suggestive of GBS/Bickerstaff brainstem encephalitis (BBE) overlap, and with electrophysiological features suggestive of AMSAN, a reported association [6] previously. The three various other patients offered AIDP and acquired negative anti-ganglioside testing. While our individual presented myoclonus limited by the palatal area, myoclonus continues to be described in BBE [7] already. Anti-GD1b have already been defined in the scientific spectral range of GBSclassically in severe sensory ataxic neuropathy (ASAN), but in AMSAN also, BBE and MFS, and are connected with more serious disease and slower recovery [5, 8, 9]. Although, the 7-week hold off of EDX boosts the question of the possible critical disease polyneuropathy componentwhich is certainly difficult to tell apart from an AMSAN, the various other features as well as the response to IVIG are and only a post-infectious immune-mediated procedure. According to a recently available overview of the books, anti-ganglioside antibodies in COVID-19-linked GBS had been positive in mere 5/36 sufferers (14%) [3]. Four brand-new anti-ganglioside positive situations, including among our patients, had been identified researching the books because of this paper and so are summarized in Desk ?Desk2.2. In COVID-19 sufferers, anti-ganglioside antibodies had been found not merely in sufferers with GBS but also in sufferers with adjustable neurological presentations (cranial neuropathy with meningo-polyradiculitis, choreic actions, myelitis) [5, 8C10] which casts question on whether these truly are.